Combining molecular targeted drugs to inhibit both cancer cells and activated stromal cells in gastric cancer.

摘要: Recent studies have revealed that PDGF plays a role in promoting progressive tumor growth several cancers, including gastric cancer. Cancer-associated fibroblasts, pericytes, and lymphatic endothelial cells stroma express high levels of receptor (PDGF-R); cancer vascular do not. Mammalian target rapamycin (mTOR) is serine/threonine kinase increases the production proteins stimulate key cellular processes such as cell proliferation, metabolism, angiogenesis. In present study, we examined effects PDGF-R tyrosine inhibitor (nilotinib) mTOR (everolimus) on an orthotopic nude mice model human Expression PDGF-B PDGF-Rβ mRNAs was associated with stromal volume. Treatment nilotinib did not suppress but significantly decreased reactivity, invasion, vessel area, pericyte coverage microvessels. contrast, treatment everolimus microvessel density reactivity. Nilotinib combination reduced both rate reaction. Target molecule-based inhibition cancer-stromal interaction appears promising effective antitumor therapy.